BioAge Labs reports Q3 2026 loss of $33.5 M and cash runway to 2029

BioAge Labs announced a net loss of $33.5 million for the third quarter of 2026, compared with $20.2 million a year earlier. The company said it holds about $352 million in cash and securities, which it expects will fund operations through 2029. Clinical updates included the first participant dosed in the QUELL‑DME Phase 2 trial for diabetic macular edema and completed enrollment in the QUELL‑CV Phase 2 obesity trial, with topline data due in late 2026 and 2027 respectively.

The expanded cash runway gives BioAge liquidity to continue its Phase 2 programs, but the widening loss highlights a higher burn rate that investors will monitor against upcoming trial readouts.

  • 1Q3 2026 net loss was $33.5 million.
  • 2Q3 2025 net loss was $20.2 million.
  • 3Cash and securities totaled approximately $352 million.
  • 4Cash and securities were $352.3 million.
  • 5First participant dosed in QUELL‑DME Phase 2 trial for diabetic macular edema.
  • 6Enrollment completed in QUELL‑CV Phase 2 trial for obesity, with topline data expected in Q4 2026.

Sources